Table 3.
Association of B. fragilis with signaling pathway genes and clinicopathological characteristics
| Characteristics (numbers (%)) | Correlation with B. fragilis (P value) | |||
|---|---|---|---|---|
| Clinicopathological | Age | < 50 | 6 (20%) | > 0.05 |
| > 50 | 24 (80%) | > 0.05 | ||
| Sex | Male | 15 (50) | > 0.05 | |
| Female | 15 (50) | |||
| Stage | I | 4 (13.3%) | > 0.05 | |
| II | 23 (76.7%) | |||
| III | 2 (6.7%) | |||
| IV | 1 (3.3%) | |||
| Histology | Adenocarcinoma | 27 (90%) | > 0.05 | |
| Mucinous | 3 (10%) | |||
| Site of primary | Colon | 20 (66.7%) | > 0.05 | |
| Rectal | 10 (33.3%) | |||
| Drinkers | 4 (13.3%) | > 0.05 | ||
| Smokers | 3 (10%) | > 0.05 | ||
| Signaling genes | WNT/ β-catenin signaling pathway | WNT | > 0.05 | |
| TCF | > 0.05 | |||
| APC | > 0.05 | |||
| CTNNB1 | < 0.05 | |||
| AXIN | < 0.05 | |||
| Apoptotic Pathways | CCND1 | > 0.05 | ||
| BCL2 | < 0.05 | |||
| BAX | > 0.05 | |||
| TP53 | > 0.05 | |||